Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF cream for prevention of postinflammatory hyperpigmentation after Q-switched Nd:YAG laser treatment of Hori nevus in Asians
TCTR20210301001Phase 3Completed
- Sponsor
- Ramathibodi Hospital Division of Dermatology
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of epidermal growth factor in Post-inflammatory hyperpigmentation (PIH) and Oculodermal melanocytosis (ODM), sponsored by Ramathibodi Hospital Division of Dermatology. Started Jul 2019; status: completed.
02
Drugs
epidermal growth factor
03
Conditions
Post-inflammatory hyperpigmentation (PIH)Oculodermal melanocytosis (ODM)
Beyond the preview
Go deeper on TCTR20210301001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210301001.